Positions

Overview

  • Dr. Markert received an A.B. degree cum laude in Biochemical Sciences from Harvard University, where he also pursued graduate studies in Applied Mathematics. He then obtained his M.D. degree from Columbia University College of Physicians and Surgeons in 1988 with a simultaneous award of a Masters in Public Health, also from Columbia University. He performed his general surgery internship, as well as his neurological surgery residency, at the University of Michigan Medical Center under Dr. Julian "Buz" Hoff during the period of 1988 to 1995. During his residency, he spent 18 months in the laboratory of Dr. Robert Martuza at Massachusetts General Hospital studying the potential application of genetically-engineered herpes simplex virus as a treatment approach for malignant glioma. He then returned to the University of Michigan where he completed his Chief Residency in 1995.

    Upon completion of his residency, he became a faculty member of the Division of Neurosurgery at the University of Alabama at Birmingham. Immediately after joining the faculty, he completed an additional research program under Dr. Bernard Roizman at the University of Chicago in the area of molecular herpes virology. In April of 1996, he returned to UAB as an Assistant Professor of Neurosurgery. There, under the mentorship of Dr. Richard B. Morawetz, he prospered in the area of clinical neuro-oncologic surgery and rose through the ranks. In 2006, he was appointed Director of the Division of Neurosurgery at the University of Alabama at Birmingham. He has been fortunate to work with an extremely talented and congenial group of faculty and residents.

    On October 1, 2013, the Division of Neurosurgery was granted Departmental status by the University of Alabama School of Medicine, and Dr. Markert was named the inaugural chair of the Department of Neurosurgery.

    Dr. Markert's research interests center around novel therapies for the treatment of malignant glioma, and translating findings from the laboratory into the clinical arena. His major interest remains the use of herpes simplex virus and other viruses as oncolytic and gene therapy vectors for the treatment of malignant brain tumors and other cancers, including malignant peripheral nerve sheath tumors.

    He has been an active participant in program project grants centered at both the University of Alabama at Birmingham and the University of Chicago under the directorship of Dr. Richard Whitley, which has resulted in several new findings in this arena and he has been Co-Director of the University of Alabama at Birmingham Brain Tumor SPORE along with Dr. Yancey Gillespie.

    Dr. Markert has been extremely active in organized neurosurgery as well, holding positions in the American Association of Neurological Surgeons, Congress of Neurological Surgeons, American Academy of Neurological Surgery, and the Society of Neurological Surgeons. He has served as President of the Southern Neurosurgical Society.

    Dr. Markert's clinical interests include neurosurgical care of benign and malignant brain and spinal tumors, including open surgery and radiosurgery, as well as other aspects of general neurosurgery. He also maintains an active portfolio of clinical trials aimed at developing new approaches for the care of neurosurgical disease.
  • Selected Publications

    Chapter

    Year Title Altmetric
    2010 Impact of dose rate on outcomes of Gamma Knife® radiosurgery in patients with face pain.  360-365. 2010
    2007 Herpesviruses as therapeutic agents.  1341-1352. 2007

    Research Overview

  • Dr. Markert's major laboratory and clinical research interests are in the development of novel treatments for brain tumors utilizing molecular biology, viral vectors, and gene therapy. His current laboratory research focuses on engineered herpes simplex virus-1 as a vector for immunologic (e.g., cytokines and cell surface antigens) and antiangiogenic means of treating primary and metastatic central nervous system neoplasms as well as combined use with novel immunotherapeutics.
  • Principal Investigator On

  • Oncolytic Immunotherapy Using Chimeric HSV C134: A Phase I Trial and Establishment of Response Indicators in Recurrent Glioma Patients  awarded by BECKMAN RESEARCH INSTITUTE (CITY OF HOPE) 2020 - 2025
  • NN106 Cytochrome C Oxidase Activity In Newly Diagnosed Glioblastoma Multiforme (GBM)  awarded by MASSACHUSETTS GENERAL HOSPITAL 2016 - 2023
  • A Phase I Trial of IRS-1 HSV C134 Administered Intratumorally in Patients with Recurrent Malignant Glioma  awarded by Gateway for Cancer Research (The) 2019 - 2022
  • A Phase 1 Study of M032, a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma  awarded by National Cancer Institute/NIH/DHHS 2017 - 2022
  • Oncolytic Immunotherapy Using Chimeric HSV C134: A Phase I Trial and Establishment of Response Indicators in Recurrent Glioma Patients  awarded by National Cancer Institute/NIH/DHHS 2018 - 2021
  • Private Grant  awarded by IMMUNOCELLULAR THERAPEUTICS 2016 - 2021
  • Wolfe Meningioma Program Project  awarded by University of California, San Francisco 2019 - 2020
  • Cytochrome C Oxidase: Biomarker In Newly Diagnosed Glioblastoma Multiforme  awarded by University of Iowa 2018 - 2020
  • Private Grant  awarded by IMMUNOCELLULAR THERAPEUTICS 2015 - 2017
  • Private Grant  awarded by NORTHWEST BIOTHERAPEUTICS 2015 - 2017
  • Engineered Herpes Simplex Virus for Treatment of Malignant Peripheral Nerve Sheath Tumors  awarded by DOD - ARMY MEDICAL RESEARCH ACQUISITION ACTIVITY 2011 - 2015
  • Engineered HSV for the Treatment of Malignant Glioma - Project 4 - Lessons from the O.R.: Using Clinical Biologic Correlates to Inform HSV Trial Design  awarded by National Cancer Institute/NIH/DHHS 2009 - 2015
  • Private Grant  awarded by IMMUNOCELLULAR THERAPEUTICS 2011 - 2014
  • Private Grant  awarded by SANBIO, INC. 2012 - 2014
  • Private Grant  awarded by ONCOLYTICS BIOTECH 2005 - 2011
  • Investigator On

  • Private Grant  awarded by BLUE EARTH DIAGNONSTICS LTD ^ 2021 - 2025
  • NRG Oncology Member Institution Clinical Trial Fixed Price Subaward Agreement  awarded by NRG ONCOLOGY FOUNDATION 2019 - 2024
  • Ph1 Study of HSV G207 in Pediatric Malignant Cerebellar Tumors IND 16294 01/05/18  awarded by Food & Drug Administration 2019 - 2022
  • Canine Immuno Neurotherapeutics  awarded by National Cancer Institute/NIH/DHHS 2017 - 2022
  • Phase 1 Trial of Engineered HSV G207 in Children with Malignant Cerebellar Brain Tumors  awarded by CANNONBALL KIDS' CANCER FOUNDATION 2019 - 2022
  • UAB Research and Education Program in Neuroscience  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2017 - 2022
  • Ph1 of HSV G207 and Radiation to Treat Pediatric Brain Tumors IND 16294 (12/10/14)  awarded by Food & Drug Administration 2016 - 2022
  • Private Grant  awarded by NOVOCURE, INC. 2019 - 2022
  • Pilot Surgical PK Study of BGB324 in Recurrent Glioblastoma Patients  awarded by Johns Hopkins University 2020 - 2021
  • Boosting the Systemic and in Situ CD4+ T-Cell Responses to Malignant Glioma by Oncolytic HSV Virotherapy  awarded by DOD - Department of Defense 2018 - 2021
  • Dual PET/Fluorescence Imaging of Glioma with an MMP-14 Activabable Peptide Probe  awarded by DOD - Department of Defense 2018 - 2021
  • Private Grant  awarded by SUNOVION PHARMACEUTICALS, INC. 2016 - 2021
  • Private Grant  awarded by CHAMPIONS ONCOLOGY 2018 - 2020
  • Expansion of G207 Trial  awarded by CANNONBALL KIDS' CANCER FOUNDATION 2017 - 2020
  • UAB NRG Oncology Master Institution Purchased Service Agreement  awarded by NRG ONCOLOGY FOUNDATION 2019
  • Intraventricular Delivery of Engineered Oncolytic Herpes Simplex Virotherapy to Treat Localized and Metastatic Pediatric Brain Tumors  awarded by DOD - ARMY MEDICAL RESEARCH ACQUISITION ACTIVITY 2015 - 2019
  • Training Program in Brain Tumor Biology  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2013 - 2019
  • Private Grant  awarded by NOVOCURE, INC. 2017 - 2019
  • UAB NRG Oncology Member Institution Purchased Service Agreement  awarded by NRG ONCOLOGY FOUNDATION 2015 - 2019
  • UAB NRG Oncology Member Institution Purchased Service Agreement  awarded by NRG ONCOLOGY FOUNDATION 2014 - 2019
  • Enhancement of lmmunovirotherapy with IDO Inhibition in Pediatric Medulloblastoma  awarded by HYUNDAI HOPE ON WHEELS 2016 - 2018
  • Cytochrome C Oxidase: Biomarker In Newly Diagnosed Glioblastoma Multiforme  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2016 - 2018
  • Cytochrome C Oxidase in Malignant Gliomas  awarded by National Cancer Institute/NIH/DHHS 2012 - 2018
  • UAB Research and Education Program in Neurology, Neurosurgery, and Neuropathology  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2012 - 2017
  • Targeting Pediatric Medulloblastoma with Engineered Herpes Simplex Virus  awarded by RALLY FOUNDATION 2016 - 2017
  • Contemporary Therapeutics for Anaplastic Gliomas  awarded by National Cancer Institute/NIH/DHHS 2011 - 2017
  • Contemporary Therapeutics for Anaplastic Gliomas - Administrative Core  awarded by National Cancer Institute/NIH/DHHS 2011 - 2016
  • Contemporary Therapeutics for Anaplastic Gliomas - Animal Models  awarded by National Cancer Institute/NIH/DHHS 2011 - 2016
  • Contemporary Therapeutics for Anaplastic Gliomas - Brain Tumor Tissue Core  awarded by National Cancer Institute/NIH/DHHS 2011 - 2016
  • Contemporary Therapeutics for Anaplastic Gliomas - Project #1  awarded by National Cancer Institute/NIH/DHHS 2011 - 2016
  • Private Grant  awarded by GUERBET 2014 - 2016
  • Improving Oncolytic Herpes Simplex Virus for Metastatic Breast Cancer  awarded by METAVIVOR 2014 - 2015
  • Renin-Angiotensin System Polymorphisms in Pathophysiology of Ruptured Cerebral Artery Aneurysms and Development of Vasospasm After SAH  awarded by Brain Aneurysm Foundation 2012 - 2015
  • The oHSV-Mediated Immune Response: Engineering Long-Term Anti-GBM Immunity  awarded by SOUTHEASTERN BRAIN TUMOR FOUNDATION 2014 - 2015
  • Engineered HSV for the Treatment of Malignant Glioma  awarded by National Cancer Institute/NIH/DHHS 2009 - 2015
  • Engineered HSV for the Treatment of Malignant Glioma - Core A. Administrative Core  awarded by National Cancer Institute/NIH/DHHS 2009 - 2015
  • Engineered HSV for the Treatment of Malignant Glioma - Project 3 - Preclinical Evaluation of Oncolytic HSV for Anaplastic Glioma Therapy  awarded by National Cancer Institute/NIH/DHHS 2009 - 2015
  • Private Grant  awarded by BRACCO DIAGNOSTICS, INC. 2014 - 2015
  • Private Grant  awarded by BRACCO DIAGNOSTICS, INC. 2012 - 2014
  • Research Training Program in Surgical Oncology  awarded by National Cancer Institute/NIH/DHHS 2007 - 2012
  • Teaching Activities

  • STP10401 - SPIRITUALITY AND MEDICINE (Spring Term 2020) 2020
  • STP10401 - SPIRITUALITY AND MEDICINE (Fall Term 2019) 2019
  • STP10401 - MEDICINE AND SPIRITUALITY (Fall Term 2019) 2019
  • STP10401 - MEDICINE AND SPIRITUALITY (Fall Term 2018) 2018
  • STP10401 - MEDICINE AND SPIRITUALITY (Fall Term 2018) 2018
  • 80-413R - NEUROSURGERY RESEARCH (Fall Term 2018) 2018
  • 80-422 - PEDIATRIC NEUROSURGERY (Fall Term 2016) 2016
  • 80-422 - PEDIATRIC NEUROSURGERY (Fall Term 2013) 2013
  • 80-422 - PEDIATRIC NEUROSURGERY (Spring Term 2013) 2013
  • 80-422 - PEDIATRIC NEUROSURGERY (Spring Term 2013) 2013
  • 80-422 - PEDIATRIC NEUROSURGERY (Spring Term 2013) 2013
  • 80-422 - PEDIATRIC NEUROSURGERY (Spring Term 2013) 2013
  • 80-422 - PEDIATRIC NEUROSURGERY (Spring Term 2013) 2013
  • 80-422 - PEDIATRIC NEUROSURGERY (Spring Term 2013) 2013
  • 80-422 - PEDIATRIC NEUROSURGERY (Spring Term 2013) 2013
  • 80-422 - PEDIATRIC NEUROSURGERY (Spring Term 2013) 2013
  • 80-422 - PEDIATRIC NEUROSURGERY (Fall Term 2012) 2012
  • 80-422 - PEDIATRIC NEUROSURGERY (Fall Term 2012) 2012
  • 80-422 - PEDIATRIC NEUROSURGERY (Fall Term 2011) 2011
  • 80-422 - PEDIATRIC NEUROSURGERY (Fall Term 2011) 2011
  • 80-422 - PEDIATRIC NEUROSURGERY (Spring Term 2011) 2011
  • 80-422 - PEDIATRIC NEUROSURGERY (Spring Term 2011) 2011
  • 80-422 - PEDIATRIC NEUROSURGERY (Spring Term 2011) 2011
  • 80-422 - PEDIATRIC NEUROSURGERY (Fall Term 2010) 2010
  • 80-422 - PEDIATRIC NEUROSURGERY (Fall Term 2010) 2010
  • 80-422 - PEDIATRIC NEUROSURGERY (Spring Term 2010) 2010
  • 80-422 - PEDIATRIC NEUROSURGERY (Spring Term 2010) 2010
  • 80-422 - PEDIATRIC NEUROSURGERY (Spring Term 2010) 2010
  • 80-422 - PEDIATRIC NEUROSURGERY (Spring Term 2010) 2010
  • 80-422 - PEDIATRIC NEUROSURGERY (Spring Term 2010) 2010
  • 80-413R - NEUROSURGERY RESEARCH (Fall Term 2009) 2009
  • 80-422 - PEDIATRIC NEUROSURGERY (Fall Term 2009) 2009
  • 80-422 - PEDIATRIC NEUROSURGERY (Fall Term 2009) 2009
  • 80-422 - PEDIATRIC NEUROSURGERY (Fall Term 2009) 2009
  • 80-422 - PEDIATRIC NEUROSURGERY (Fall Term 2009) 2009
  • 80-422 - PEDIATRIC NEUROSURGERY (Fall Term 2009) 2009
  • 80-422 - PEDIATRIC NEUROSURGERY (Fall Term 2009) 2009
  • 80-422 - PEDIATRIC NEUROSURGERY (Spring Term 2008) 2008
  • 80-422 - PEDIATRIC NEUROSURGERY (Spring Term 2008) 2008
  • 80-422 - PEDIATRIC NEUROSURGERY (Spring Term 2008) 2008
  • 80-422 - PEDIATRIC NEUROSURGERY (Spring Term 2008) 2008
  • 80-422 - PEDIATRIC NEUROSURGERY (Fall Term 2007) 2007
  • 80-422 - PEDIATRIC NEUROSURGERY (Fall Term 2007) 2007
  • 80-422 - PEDIATRIC NEUROSURGERY (Fall Term 2007) 2007
  • 80-422 - PEDIATRIC NEUROSURGERY (Spring Term 2007) 2007
  • 80-422 - PEDIATRIC NEUROSURGERY (Spring Term 2007) 2007
  • 80-422 - PEDIATRIC NEUROSURGERY (Spring Term 2007) 2007
  • 80-422 - PEDIATRIC NEUROSURGERY (Spring Term 2007) 2007
  • 80-422 - PEDIATRIC NEUROSURGERY (Spring Term 2007) 2007
  • Education And Training

  • Massachusetts General Hospital, Postdoctoral Fellowship
  • Doctor of Medicine, Columbia University 1988
  • Master of Public Health, Columbia University 1988
  • Bachelor of Arts in Biochemistry, Harvard University 1983
  • University of Michigan Hospitals & Health Centers, Internship 1989
  • University of Michigan Hospitals & Health Centers, Residency 1995
  • Full Name

  • James Markert